Several risk factors like obesity and hyperlipidemia were described for endometrial cancer. Here, the nuclear NAD-dependent histone-deacetylase Sirtuin1 (SIRT1) seems to be important. SIRT1 is also involved in cell regulatory mechanisms and can serve as tumor promotor or suppressor. Its role in tumor biology is not clear yet. In this study, we evaluated and correlated the SIRT1 expression with patients' tumor characteristics in endometrioid and clear-cell cancer of the uterus. 65 paraffin-embedded samples of patients with endometrial and clear-cell cancer of the uterus were immunohistochemically stained and SIRT1 expression was evaluated by immunoreactive score. The results were correlated to clinical and pathological tumor characteristics as well as to the expression of ARID1A and β-Catenin. The staining was significantly more intensive in uterine endometrioid carcinoma compared to uterine clear-cell carcinoma (p = 0.007). The expression of SIRT1 correlated significantly with the membranous expression of β-Catenin (p = 0.028) and ARID1A (p = 0.021). Patients with positive Sirtuin1 expression had a significantly better progression-free survival (p = 0.042), the overall survival showed a trend towards a better prognosis (p = 0.070). SIRT1 expression seems to be associated with improved progression-free survival in uterine cancer (endometrioid and clear-cell) and is correlated to the tumor suppressors β-Catenin and ARID1A. Further studies are necessary to elucidate the role of SIRT1 in uterine and ovarian cancer and its potential as a therapeutic target.

中文翻译：

---

Sirtuin1在子宫内膜和透明细胞子宫癌中的表达和存活率。

描述了子宫内膜癌的几种危险因素，例如肥胖和高脂血症。在这里，核NAD依赖的组蛋白脱乙酰基酶Sirtuin1（SIRT1）似乎很重要。SIRT1也参与细胞调节机制，可以作为肿瘤的促进剂或抑制剂。其在肿瘤生物学中的作用尚不清楚。在这项研究中，我们评估了SIRT1的表达并将其与子宫内膜样癌和子宫透明细胞癌患者的肿瘤特征相关联。对65例子宫内膜癌和透明细胞癌患者石蜡包埋的样品进行免疫组织化学染色，并通过免疫反应评分评估SIRT1表达。结果与临床和病理肿瘤特征以及ARID1A和β-连环蛋白的表达相关。与子宫透明细胞癌相比，子宫内膜样癌的染色明显更强（p = 0.007）。SIRT1的表达与β-Catenin的膜表达（p = 0.028）和ARID1A（p = 0.021）显着相关。Sirtuin1表达阳性的患者的无进展生存期明显更好（p = 0.042），总生存期显示了更好的预后趋势（p = 0.070）。SIRT1表达似乎与子宫癌（子宫内膜样和透明细胞）的无进展生存期改善有关，并且与肿瘤抑制因子β-Catenin和ARID1A相关。为了阐明SIRT1在子宫癌和卵巢癌中的作用及其作为治疗靶标的潜力，有必要进行进一步的研究。SIRT1的表达与β-Catenin的膜表达（p = 0.028）和ARID1A（p = 0.021）显着相关。Sirtuin1表达阳性的患者的无进展生存期明显更好（p = 0.042），总生存期显示出更好的预后趋势（p = 0.070）。SIRT1表达似乎与子宫癌（子宫内膜样和透明细胞）的无进展生存期改善有关，并且与肿瘤抑制因子β-Catenin和ARID1A相关。为了阐明SIRT1在子宫癌和卵巢癌中的作用及其作为治疗靶标的潜力，有必要进行进一步的研究。SIRT1的表达与β-Catenin的膜表达（p = 0.028）和ARID1A（p = 0.021）显着相关。Sirtuin1表达阳性的患者的无进展生存期明显更好（p = 0.042），总生存期显示了更好的预后趋势（p = 0.070）。SIRT1表达似乎与子宫癌（子宫内膜样和透明细胞）的无进展生存期改善有关，并且与肿瘤抑制因子β-Catenin和ARID1A相关。为了阐明SIRT1在子宫癌和卵巢癌中的作用及其作为治疗靶标的潜力，有必要进行进一步的研究。Sirtuin1表达阳性的患者的无进展生存期明显更好（p = 0.042），总生存期显示出更好的预后趋势（p = 0.070）。SIRT1表达似乎与子宫癌（子宫内膜样和透明细胞）的无进展生存期改善有关，并且与肿瘤抑制因子β-Catenin和ARID1A相关。为了阐明SIRT1在子宫癌和卵巢癌中的作用及其作为治疗靶标的潜力，有必要进行进一步的研究。Sirtuin1表达阳性的患者的无进展生存期明显更好（p = 0.042），总生存期显示出更好的预后趋势（p = 0.070）。SIRT1表达似乎与子宫癌（子宫内膜样和透明细胞）的无进展生存期改善有关，并且与肿瘤抑制因子β-Catenin和ARID1A相关。为了阐明SIRT1在子宫癌和卵巢癌中的作用及其作为治疗靶标的潜力，有必要进行进一步的研究。